Taking the Kidneys to Heart: Managing CKD-Related Anemia With Emerging HIF-PHIs

 

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by an educational grant from GlaxoSmithKline.

PROGRAM OVERVIEW

Anemia is a common disease sequela of chronic kidney disease (CKD) that worsens and complicates the bidirectional disease continuum between the kidneys and heart. Anemia in CKD can be treated, which can extend the lives of CKD patients as well as reduce hospitalizations and improve quality of life, yet it is persistently undermanaged because current treatments are in and of themselves linked with increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance.

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to potentially change the treatment paradigm for patients with CKD-related anemia. Join our esteemed faculty for a review of current and emerging treatments, as if or when new therapies are approved, physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the clinical trial data that support their use in appropriately selected patients.

FACULTY

Biff F. Palmer, MD, FACP, FASN
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Release date: December 16, 2022
Expiration date: December 16, 2023
Estimated time to complete activity: 60 minutes
TARGET AUDIENCE

This educational activity has been designed to meet the needs of hospitalists, general internists, subspecialists, and family practitioners caring for hospitalized patients.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Clarify the disease burden imposed by untreated or undertreated anemia in patients with CKD, including in racially diverse patients
  • Correlate the pathophysiology of anemia in CKD with viable therapeutic targets
  • Identify appropriate candidates for emerging CKD-related anemia treatments among patients on or not on dialysis based on efficacy and safety data from recent clinical trials
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CE/CME credit for this activity. During the period of December 16, 2022 through December 16, 2023, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must complete the pretest, view the material, and complete the posttest and evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%. Pharmacists must check the CPE Monitor to access their credits within 60 days of the activity. Credit cannot be issued after 60 days.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CE/CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-22-240-H01-P.)

This is a knowledge-based activity.

FEE INFORMATION

There is no fee for completing this program.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integrity Continuing Education, Inc. and Global Education Group are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by Integrity Continuing Education, Inc. and Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integrity Continuing Education, Inc. and Global Education Group to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CE/CME activities:

Biff F. Palmer MD has no real or apparent conflicts of interest to disclose.

The planners and managers at Integrity Continuing Education, Inc. and Global Education Group have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest